postdocs Archives - Page 6 of 7 - Sanford Burnham Prebys
Institute News

Celebrating the next generation of biomedical trailblazers at the 19th annual Fishman Fund Awards

AuthorMonica May
Date

September 22, 2020

Four talented early-career researchers were awarded prestigious Fishman Fund Awards.

When Dr. William and Lillian Fishman founded our Institute in 1976, they knew that nurturing the next generation of scientists was just as important as advancing cutting-edge research. Today, their values live on in the form of the Fishman Fund Awards, which help exceptional postdoctoral researchers develop into scientific leaders.

On September 24, four talented early-career researchers received the prestigious award during an inspiring virtual ceremony. Generous benefactors, past award winners, and family and friends tuned into the event, which featured remarks from Institute president Kristiina Vuori, MD, PhD; professor and Fishman Fund Award recipient José Luis Millán, PhD; Fishman Fund co-founder Reena Horowitz and co-founder designee Jeanne Jones.

“The Fishmans firmly believed in helping brilliant early-career postdoctoral scientists become great principal investigators,” says Ms. Horowitz, who established the Fishman Fund Awards in 2001 with her late friend Mary Bradley. “Our goal with these awards is to encourage and support these researchers in their quest for the next great medical breakthroughs, which might one day be able to save the lives of our family members, friends and neighbors.”

Fishman Fund winners undergo a rigorous selection process that includes a personal interview and a presentation to the selection committee. All winners receive a $10,000 career development award that can be used to attend workshops, network and travel to national and international conferences to learn about the latest developments in their research fields. The winner of the Fishman Fund Fellowship receives a two-year salary stipend in addition to the professional development funding.

Meet this year’s Fishman Fund Award winners

Fishman Fund Fellowship Award

Kyungsoo Shin, PhD, grew up in Halifax, Nova Scotia, in Canada, where he also attended Dalhousie University for his undergraduate and graduate studies. Dr. Shin works in the laboratory of Dr. Francesca Marassi, where he is advancing a potential treatment for age-related macular degeneration, a leading cause of vision loss in people over the age of 60. Dr. Shin recently showed that a protein called vitronectin is the likely cause of the pebble-like deposits in the back of the eye that underlie the disease. With this information, scientists can now work toward a treatment to prevent vision loss.

Dr. Shin’s career goal is to become an independent researcher focused on understanding how cellular membranes—gatekeepers that regulate what enters or exits a cell—are involved in disease. He hopes to mentor and inspire the next generation of scientists to advance our understanding of human biology.
 

Fishman Fund Career Development Awards

Marie Berenguer, PhD, grew up near Paris and went to school in Bordeaux. She is currently studying in the laboratory of Dr. Gregg Duester and focuses on how a compound called retinoic acid affects the way embryos are formed. Her work may open new avenues to prevent and treat birth defects.

Dr. Berenguer’s career goal is to become a principal investigator and lecturer in genetics and developmental biology. By leading her own research team, she hopes to improve our understanding of genetic diseases and lay the foundation for future therapies.

Daniela Dengler, PhD, is from Germany, where she studied pharmacy and worked in a pharmacy for a year before she decided to pursue her PhD at the Friedrich-Alexander University in Erlangen-Nuremberg, Germany. Dr. Dengler works in the Conrad Prebys Center for Chemical Genomics with Dr. Eduard Sergienko. She is searching for new drugs that bind to proteins called G-protein coupled receptors (GPCRs), which mediate many physiological processes in the body. More than 30% of all FDA-approved drugs act on GPCRs.

Dr. Dengler’s career goal is to become a project leader in biotech, where she wants to combine her background in chemistry with her knowledge in assay development and high-throughput screening to find drugs for unmet medical needs.

Chiara Nicoletti, PhD, grew up in Gela, in Sicily, and received her PhD at the University of Padua in northern Italy. Dr. Nicletti is in Dr. Pier Lorenzo Puri’s lab and is studying the links between genetic sequences and risk of disease. Her research will open new avenues to help clinicians practice personalized medicine—including predicting who is likely to get a disease, how to prevent it, how to treat it and perhaps even cure the condition.

Dr. Nicoletti’s career goal is to become a principal investigator, leading her own research team that focuses on integrating foundational research with everyday medical practice to improve human health.

Watch the Fishman Fund Awards ceremony, which featured remarks from Institute president Kristiina Vuori, MD, PhD; professor and Fishman Fund Award recipient José Luis Millán, PhD; Fishman Fund co-founder Reena Horowitz and co-founder designee Jeanne Jones.

Learn more about the Fishman Fund, or, donate now, to support future scientific leaders.

Institute News

Meet molecular biologist Kyungsoo Shin

AuthorMonica May
Date

September 22, 2020

Kyungsoo Shin is the winner of this year’s prestigious Fishman Fund Fellowship Award, which helps talented early-career researchers become scientific leaders

While growing up, Kyungsoo Shin always found himself drawn to science. Learning how the body works was endlessly fascinating to him. But it wasn’t until he was in the middle of his PhD that he became officially hooked on research.

“I was doing a long 16-hour experiment, and around 9 or 10 p.m. I started getting really positive results. I was so excited that I called my supervisors at the time,” recalls Shin. “Even though it was so late, they were just as happy as I was! That was my first introduction to how intoxicating research can be, and the power of a supportive community.”

Today, as a postdoctoral researcher at Sanford Burnham Prebys, Shin is applying his passion for discovery to an area of great need: finding a treatment for dry age-related macular degeneration (AMD). No treatments currently exist for the common condition, which is the main cause of vision loss for people over the age of 60. As a new father, this research became especially meaningful to Shin.

“My son is 3 months old, and just started to smile and laugh,” says Shin. “I couldn’t imagine one day not being able to see him, or my grandchildren. If I had dry AMD, I probably wouldn’t be able to even drive to go see him. I don’t want to imagine that sort of life for anyone.”

Working with a world-renowned scientist

Shin has found a wise mentor in Professor Francesca Marassi, PhD, one of the world’s leading experts on nuclear magnetic resonance (NMR) spectroscopy. This technology allows scientists to see the shape of a protein, which enables rational drug design. When the job posting first appeared, Shin was writing his PhD thesis—but his supervisor told him to stop writing and apply to the position immediately. The opportunity to work with Marassi was too important.

“Learning from her has fundamentally changed who I am as a scientist,” says Shin. “Before I used to think in terms of completing projects. Now I ‘follow the science,’ which means let the data lead me to my next step.”

This approach has proved successful: Marassi and Shin recently uncovered a new drug target for dry AMD. Using NMR and other cutting-edge technologies located at the Institute, they deciphered the shape of a protein called vitronectin. Then they showed that the sticky, propeller-shaped protein likely “seeds” the formation of pebble-like structures in the back of the eye that cause vision loss.

Fishman Fund Award advances key research

Now, with the support of the Fishman Fund Fellowship Award—which provides a salary stipend and $10,000 for career development—Shin can attend scientific conferences that will help him think outside of the box and grow as a scientist. Receiving an award in honor of the Fishmans—who started the Institute after reaching mandatory retirement age—is special to Shin.

“The Fishmans were so devoted to pushing our understanding of human health that they continued their research even when they didn’t have to,” says Shin. “To receive a fellowship that is named after such inspirational and honorable people is truly an honor. I have a great sense of responsibility to advance research that will have a positive impact on humanity, and could one day benefit my son or his children.”

Sanford Burnham Prebys is grateful to the generous Fishman Fund donors who make the career development awards possible. Learn more about the Fishman Fund, or donate now, to support future scientific leaders.

Institute News

18th Annual Fishman Fund Award ceremony celebrates the next generation of biomedical trailblazers

AuthorSusan Gammon
Date

September 23, 2019

Three talented early-career researchers were presented with a prestigious Fishman Fund Award at the annual ceremony on September 19. More than 100 generous benefactors, past award winners and family and friends joined the celebration held at the Sanford Consortium. The awards honor the Institute’s founders, Dr. William and Lillian Fishman.

Reena Horowitz, who along with her close friend Mary Bradley established the Fishman Fund Awards, welcomed the audience and shared how the Fishmans truly believed that young researchers need a boost from time to time—and that these awards do exactly that. Recipients who are selected from a pool of Sanford Burnham Prebys postdocs use the $10,000 stipend to attend workshops, network and travel to national and international conferences to learn about the latest developments in their research fields. 

“The young researchers at Sanford Burnham Prebys make discoveries that have an impact in San Diego as well as helping advance science and health around the world,” said Horowitz. “The Institute motto could not ring truer: From Research the Power to Cure.”

Professor Hudson Freeze—one of the very first Fishman Fund Award winners and now director of the Institute’s Human Genetics Program—shared how his nearly 40 years of research has established him as a magnet for a global community of families seeking treatments for rare childhood diseases. He encouraged this year’s winners to take advantage of working in a world-class research center and to pursue meaningful research that will open new avenues to improve human health.

Jennifer Hope, PhD, was presented with the Lenka Finci and Erna Viterbi Fund Prize by Horowitz and Institute supporter Judy White. Dr. Hope works in the laboratory of Professor Linda Bradley, where she is studying cellular and molecular mechanisms that drive the development of T cells that attack cancer. Jennifer’s career goal is to become an independent investigator focused on research to promote patient responsiveness to cancer therapies.

Mafalda Loreti, PhD, was presented with the Jeanne Jones and Kathryn Fishback Fund Prize by Fishman Fund co-founder designee Jeanne Jones and longtime Institute supporter Sam Horowitz. Dr. Loreti is studying the mechanisms that promote muscle growth and repair in the laboratory of Associate Professor Alessandra Sacco. Her career goal is to become an independent researcher in an academic setting, where she will explore the biology of muscle pathologies and approaches to improve muscle health.

Aaron Havas, PhD, received the Reena Horowitz and Mary Bradley Fishman Fund Prize from Horowitz and Institute supporter Doreen Schonbrun. Dr. Havas works in the lab of Professor Peter Adams, where he studies how aging affects gene regulation. His career goal is to work in the biotech industry exploring drugs that target the process to promote healthy aging.

Since the fund’s inception in 2001, 64 prizes have been awarded. Every other year, a 24-month fellowship that provides salary support is given to a deserving postdoc. The fellowship was awarded in 2018, so it will be given again at next year’s ceremony.

The generosity of our Fishman Fund donors enables the tradition of providing career advancement opportunities. On behalf of all of us at Sanford Burnham Prebys, we thank you for your support.

Institute News

SBP scientist presents at Fleet Science Center to help the public better understand precision medicine

AuthorMonica May
Date

January 29, 2019

From how much coffee we can tolerate to the amount of weight we can lift, our bodies differ from one another in myriad ways. But when it comes to medicine, historically every patient with the same disease or condition has received the same treatment—even though individual responses vary wildly. 

Now, technological advances are enabling medicine to move from “one size fits all” to tailored treatments based upon one’s specific genes. This approach is called precision medicine. 

This December, under the dome of the Fleet Science Center’s IMAX theater, Jessica Rusert, PhD, a postdoctoral researcher in the lab of Robert Wechsler-Reya, PhD, explained the promise and potential of precision medicine to a crowd of nearly 100 people as part of the museum’s Senior Monday presentation series (if interested, check out the 2019 schedule). 

We caught up with Rusert to learn more about the goals of precision medicine and her work in the Wechsler-Reya lab. 

Before the advent of precision medicine, how did doctors typically treat patients? 
In the past, all patients who had the same disease—say, breast cancer—received the same treatment, which was most likely surgery followed by chemotherapy and radiation. Your treatment might change if you have more advanced disease—in which case the approach would be more aggressive. But typically treatment was based upon physical criteria: the location of the tumor, your symptoms or how the tumor looks under a microscope. That’s not to say this is a bad approach; it was simply the only information doctors and scientists had to work from. 

What catalyzed the movement from one size fits all to personalized treatment?
The invention of DNA sequencing has revolutionized personalized medicine. As the cost of sequencing decreases and the use of the technology swells, we will glean even more information from the genome, and personalized medicine will expand further to new areas. 

What is the ultimate goal of precision medicine? 
Precision medicine aims to treat the right patient, with the right drug, at the right time.

How far away is precision medicine from this goal? 
We are making inroads, but it is still early days for precision medicine. Currently, we are making the most progress in cancer. But despite these advances, the vast majority of cancers—including the pediatric brain cancer our lab studies—are treated with surgery, chemotherapy and radiation. 

As scientists learn more about the underlying cause of disease(s), precision medicine will expand to new cancers and new disease areas. These advances are happening now, and for some cancers, the outlook is already much better than it used to be. Perhaps one day we will have personalized treatments for schizophrenia and autism. The approach is mostly limited by how much we know about a disease. 

What is an example of a precision medicine? 
The breast cancer treatment Herceptin® is a great example of a precision medicine. 

Cells in our body use molecular antennae called receptors to sense and respond to their environment. One receptor, called HER2, controls cellular growth, and is involved in the development of breast cancer. 

Herceptin works by blocking the HER2 receptor. Then, the receptor can’t tell cells to grow, and tumor growth stops. 

However, this medicine only works if your tumor cells have this receptor. HER2-positive breast cancer means your cells have this receptor. HER2-negative breast cancer means you do not have the receptor, and thus Herceptin wouldn’t work for you. So people with breast cancer are tested to ensure they have the HER2 receptor before receiving Herceptin. 

Herceptin has saved thousands of lives. It is a true testament to the power of precision medicine. 

What was a popular question from the audience?
A lot of people wondered if there’s a way to prevent cancer. This is understandable—cancer is scary, and we want to do all we can to stop it. But it’s a difficult question to answer. The science isn’t there yet. We are only just now starting to understand how to help people who have acute disease. We may understand how to prevent cancer one day—but that will take decades, not years. 

How do you use precision medicine in your work?
In the Wechsler-Reya lab, we are working to find personalized treatments for children with brain cancer. We are studying the most common malignant pediatric brain cancer, called medulloblastoma. 

Children with medulloblastoma undergo surgery to remove the tumor and then undergo chemotherapy and radiation treatment. This treatment is hard for adults to go through—and even more devastating for a developing child. The treatment leaves long-term effects, including cognitive impairment and increased risk of other cancers due to the DNA damage caused. A treatment that reduces or eliminates these side effects is urgently needed. 

Scientists are learning that medulloblastoma is not one cancer, but actually four clearly defined subgroups. We are working to better understand these subgroups so we can develop targeted treatments that are customized to each cancer type (read the lab’s recent discovery). 

Where is precision medicine heading in the future? 
Right now, most precision medicine focuses on our DNA, but there are many other ways we differ from one another. But increasingly, scientists are working toward precision medicine that also takes into account RNA, proteins, our metabolism, the epigenome (molecular tags on DNA) and more.

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

American Heart Association awards postdoctoral fellowship to SBP scientist

AuthorMonica May
Date

January 23, 2019

It’s no surprise that muscles are important to our metabolism: it’s why building muscle at the gym can accelerate weight loss. 

Scientists are particularly interested in how muscle metabolism affects the heart, arguably the most important muscle in the body. With heart disease remaining the number-one killer of men and women in the U.S., the hunt is on to better understand the molecular mechanisms of the heart so we can develop better treatments. (Learn more about heart disease at our upcoming SBP Insights event.) 

Research is revealing that altered communications between skeletal and heart muscle increases the risk of heart disease. But the molecular mechanisms behind this link are currently unknown. 

Now, the American Heart Association has awarded a two-year postdoctoral fellowship to SBP’s Chiara Nicoletti, PhD, to study the genetic basis of metabolic changes in skeletal muscle that ultimately lead to heart disease. Nicoletti works in the lab of Pier Lorenzo Puri, MD, professor in the Development, Aging and Regeneration Program at SBP. 

Findings from Nicoletti’s work could uncover therapeutic targets for heart disease and/or lead to a prognostic tool that could predict heart disease risk. Both developments would be much-needed advances in the battle against heart disease. 

Interested in keeping up with SBP’s latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

Usue Etxaniz Irigoien awarded Fishman Fund Fellowship

AuthorSusan Gammon
Date

June 13, 2018

Congratulations to SBP postdoc Usue Etxaniz Irigoien, PhD—the recipient of the 2018 Fishman Fund Fellowship. This prestigious award is a “super stipend” given to exceptional young researchers in recognition of their research accomplishments and in support of their future research plans. Etxaniz Irigoien will use the financial support to continue her research on muscle biology—explorations that may lead to treatments for disorders such as muscular dystrophy and amyotrophic lateral sclerosis (ALS).

“I’m honored to receive this special fellowship,” says Etxaniz Irigoien. “I came to SBP to pursue my interest in muscle development and regeneration, and have been so fortunate to work with world-renowned, collaborative scientists with similar interests. This award makes the whole experience even better, and secures my ability to continue making discoveries that may one day improve human health.”

Etxaniz Irigoien, a postdoc in the laboratory of Pier Lorenzo Puri, MD, PhD, professor in the Development, Aging and Regeneration Program at SBP, studies a type of muscle cell called fibro-adipogenic progenitors, or FAPs. These are the cells that act as intramuscular sensors and effectors, which means that FAPs can detect “alert” signals and generate different responses by orchestrating other cells’ activity upon different muscle perturbations. In healthy conditions, when muscle suffers an injury, FAPs cue muscle stem cells to repair the damaged muscle fibers. However, in disease (i.e., muscular dystrophies or neuromuscular disorders such as ALS), FAPs’ activity results in fibrosis, fat deposits and other detrimental events that contribute to disease progression.

“If we can begin to uncover how FAPs support muscle regeneration, or contribute to muscle degeneration in different environments, i.e., healthy versus disease tissue, we can look for potential therapeutics that will move the process toward the healthy state,” says Etxaniz Irigoien. “This is so important because today there are no effective therapeutics for dystrophies or ALS, and it’s time we make progress to help these patients.”

Etxaniz Irigoien has come a long way from her hometown of Getaria, a small fishing village located in the Basque Country of Northern Spain. She says, “I had a biology teacher who inspired my interest in science, and I have always known I wanted a career in research. My family, most of whom still live in Getaria, are very supportive and excited about my career and this award. In fact, some of them will be traveling to San Diego for the Fishman Fund ceremony in September. I’m very excited for them to visit SBP and meet some of my colleagues.”

Getaria, located in the Basque Country of Northern Spain
Getaria, located in the Basque Country of Northern Spain
 
Usue as young girl in Getaria
Usue as young girl in Getaria

The Fishman Fund Fellowship
The Fishman Fund Fellowship was established in honor of Dr. William and Mrs. Lillian Fishman, co-founders of SBP. Applicants must have a doctoral degree, no more than five years of training at any institution, and at least one full year of postdoctoral study at SBP. Fellowship support is for two years in length and covers salary, benefits and a professional-development allowance.

SBP is thankful for the generous Fishman Fund donors who make career development awards possible. If you would like to donate to the Fishman Fund to support young scientists click here.

Institute News

16th Annual SBP Postdoctoral Research Symposium

AuthorSusan Gammon
Date

September 22, 2017

Future scientific leaders gathered to attend SBP’s 16th Annual Postdoctoral Research Symposium—an event that showcased the talent of our young researchers, many of whom are in the midst of scholarly training beyond their doctoral degree.

The day began with a workshop led by Professor Carl Ware, PhD, titled, “Science Funding in Uncertain Times.” For the young scientists in the audience, they gleaned valuable insights on when and where they should seek funding, and the types of publications and collaborations they should aim for. As faculty positions in academia become increasingly competitive, a solid track record of funding, publications and collaborations become key measures used to make hiring decisions.

Keynote speaker Peter Schultz, PhD, CEO of The Scripps Research Institute, gave an impressive talk on his efforts to expand the genetic code. Schultz, a chemist by training, is inspired to create new amino acids, beyond the 20 essential ones in existence, to advance cancer therapies, create new vaccines, novel chemical probes and improved antibiotics. The audience was truly “wowed” by his vision and track record of achievements.

The agenda followed with 20-minute talks by postdocs including:

• David Sala Cano, PhD (Sacco Lab)
• Yang Wei, PhD (Petroski Lab)
• Maria Missinato, PhD (Colas Lab)
• Anjali Gupta, graduate student (Ocorr Lab)
• Marco Maruggi, graduate student (Powis Lab)
• Clyde Campbell (graduate student Dong Lab)
• Jing Yong, PhD (Kaufman Lab)
• Laura Martin-Sancho, PhD (Chanda Lab)

The event closed with a poster session featuring more than 30 presentations by SBP’s best and brightest young scientists. Many congratulations to all that participated in the Symposium, and thanks to the organizers at the Office of Education, Training, & International Services (OETIS) at SBP.

Institute News

Monika Schneider, former SBP postdoc, now a health policy analyst in DC

Authorjmoore
Date

April 26, 2016

This is part of a series on what past SBP postdocs are doing now.

Monika Schneider, PhD, was a postdoctoral researcher in the laboratory of Sumit Chanda, PhD, professor and director of the Immunity and Pathogenesis Program, from 2012-2014, where she studied how the immune system recognizes and clears HIV. After serving as a science policy advocate at the American Association of Immunologists, she recently took a position with the Duke-Margolis Center for Health Policy.

What’s your job like— what do you do every day?

In my current position, I develop policy solutions to issues that affect drug development and health care. My duties include research to identify the main players, current policy, and gaps in knowledge or process; convening meetings with relevant stakeholders; and writing up reports on recommended policies and pathways for implementation.

What do you enjoy most about it and why?

I really enjoy learning new things, and here I get to learn about what has to happen after discovery of a drug at a research institution before it can be marketed. I also get to make an impact on how drug development is prioritized and paid for.

What do you hope to accomplish in your career?

It’s the same as what initially drew me to science in general and immunology in particular: helping to reduce the suffering caused by disease. I hope to develop policies that will result in smarter, faster, and less costly drug development.

What did you gain from your postdoc experience at SBP? 

I really appreciated the translational aspect of much of the research at SBP. I also feel that during my time as a postdoc, I learned how to do team science. Having multiple projects, and collaborators that were on the other side of the country, really strengthened my organizational and project management skills. 

How did you find your first job after your postdoc? Was it challenging?

I found my first job through a job posting site. It was not challenging for me mostly due to good timing and fit—the organization’s leadership knew my references. However, I believe that my involvement in student government and the SBP Science Network (SBP-SN) gave me a leg up.

Were you looking specifically for jobs in science policy?

No, I was also considering scientific program management and medical writing. I really enjoy discussing science (I always liked lab meetings) and technical writing, so I was looking for positions where I could serve as a liaison between scientists and government, business interests, or the public.

What do you miss most and least about San Diego?

I miss the plethora of breweries, Mexican food, and, of course, the friends I made while living there. I do not miss sitting in traffic to get to work (I take the metro now) or the lack of leafy trees and grass.

Institute News

A day in the life of a cancer researcher

AuthorGuest Blogger
Date

October 29, 2015

This story was written by Petrus De Jong, MD, PhD

I hear noise from our boys’ room but decide to check my e-mail first. Waking up in Pacific Time means that e-mails from other time zones are already piling up. Breakfast for everyone and black coffee for me are the next priority.

With the sun roof open, it is only a short commute to Sanford Burnham Prebys. Along the way I pass miles of Pacific coastline, as well as the sites where decades of scientific discoveries have modernized health care. The drive takes less than fifteen minutes, but my personal road to becoming a medical researcher spans almost 15 years. Being part of SBP’s scientific community now, at the frontier of modern medical science, is a real privilege.

While the computer is starting up, I put on my white lab coat to check the cancer cell lines that we have growing for our experimental drug tests. Our lab, led by Prof. Garth Powis, is focused on finding new types of therapeutics for cancer based on unique vulnerabilities of tumor cells. Although it might sound strange, we have to be sure our cancer cells are ‘healthy’ enough for our experiments. We know every detail of their normal shape and growth pattern. I glance through the microscope and know that the cells are good for our next experiment.

lab

Today I am testing the specificity of new drugs that are designed to cut the fuel supply of rapidly growing tumor cells. We can measure whether our new compounds are hitting their target with high precision by using some genetic tricks. If the tricks work, the cancer cells will glow a green color in the dark. I turn off the lights, then turn on the fluorescent laser and look through the microscope. The cells light up in neon green—part one of the experiment worked! The next step is to test whether the drugs have an effect on tumor cell growth.

cancer-cells

Cancer research is teamwork. Today’s experiment was designed based on the work of chemists from Texas (UT Austin), together with protein biologists and medical biologists from SBP. After I put the cells back in the incubator, I grab my notebook and knock on Dr. Powis’ door—even though it’s already open. We have a conference call today with our collaborators to discuss the latest results and future directions. During the technical discussion, I realize that our drug not only has the potential to target and kill cancer cells, but has taught us things we never knew about how normal and tumor cells regulate their energy needs. And this is important, because the more we understand about the fundamental processes that cells use to get energy, the greater the number of opportunities.

Everyone is anxious to hear the results of the next round of experiments and after refueling with a strong espresso, I return to the lab. I am testing two different drugs on the green cells. One of the drugs is bright yellow, the other is colorless. After carefully preparing various drug concentrations, they are added to the cells which then go back into the incubator. It will take 24 hours before I know the results.

I carefully write down the details of today’s experiment in my lab notebook. The remainder of the day is taken up analyzing experimental data, generating figures for publication, preparing for the next lab meeting, sending requests to speakers for upcoming events, and more. Before turning off my computer, I write down my to-do list for tomorrow. I will first check the results from today’s experiment realizing I am not the only one eager to learn about the results.

Finally I hang up my lab coat, hoping to be one step closer to new cures for tomorrow.